Adaptive Biotechnologies Corporation 1HM.MU Stock
Adaptive Biotechnologies Corporation Price Chart
Adaptive Biotechnologies Corporation 1HM.MU Financial and Trading Overview
| Adaptive Biotechnologies Corporation stock price | 2.49 EUR |
| Previous Close | 8.02 EUR |
| Open | 8.02 EUR |
| Bid | 7.87 EUR x N/A |
| Ask | 8.04 EUR x N/A |
| Day's Range | 8.02 - 8.02 EUR |
| 52 Week Range | 5.8 - 12.37 EUR |
| Volume | 200 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 1.16B EUR |
| Beta (5Y Monthly) | 1.170431 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.45 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
1HM.MU Valuation Measures
| Enterprise Value | 1.24B EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.2817783 |
| Price/Book (mrq) | 2.7301805 |
| Enterprise Value/Revenue | 6.702 |
| Enterprise Value/EBITDA | -7.207 |
Trading Information
Adaptive Biotechnologies Corporation Stock Price History
| Beta (5Y Monthly) | 1.170431 |
| 52-Week Change | 20.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.37 EUR |
| 52 Week Low | 5.8 EUR |
| 50-Day Moving Average | 6.91 EUR |
| 200-Day Moving Average | 7.73 EUR |
1HM.MU Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 144.31M |
| Float | 98.31M |
| Short Ratio | N/A |
| % Held by Insiders | 2.30% |
| % Held by Institutions | 91.25% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -105.86% |
| Operating Margin (ttm) | -104.54% |
| Gross Margin | -8.073% |
| EBITDA Margin | -92.99% |
Management Effectiveness
| Return on Assets (ttm) | -14.60% |
| Return on Equity (ttm) | -39.96% |
Income Statement
| Revenue (ttm) | 184.34M EUR |
| Revenue Per Share (ttm) | 1.29 EUR |
| Quarterly Revenue Growth (yoy) | -2.50% |
| Gross Profit (ttm) | -13657000 EUR |
| EBITDA | -171424992 EUR |
| Net Income Avi to Common (ttm) | -195154000 EUR |
| Diluted EPS (ttm) | -1.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 440.7M EUR |
| Total Cash Per Share (mrq) | 3.05 EUR |
| Total Debt (mrq) | 232.79M EUR |
| Total Debt/Equity (mrq) | 54.91 EUR |
| Current Ratio (mrq) | 5.564 |
| Book Value Per Share (mrq) | 2.939 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -178644000 EUR |
| Levered Free Cash Flow (ttm) | -93709624 EUR |
Profile of Adaptive Biotechnologies Corporation
| Country | Germany |
| State | WA |
| City | Seattle |
| Address | 1165 Eastlake Avenue East |
| ZIP | 98109 |
| Phone | 206 659 0067 |
| Website | https://www.adaptivebiotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 790 |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Q&A For Adaptive Biotechnologies Corporation Stock
What is a current 1HM.MU stock price?
Adaptive Biotechnologies Corporation 1HM.MU stock price today per share is 2.49 EUR.
How to purchase Adaptive Biotechnologies Corporation stock?
You can buy 1HM.MU shares on the Munich exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adaptive Biotechnologies Corporation?
The stock symbol or ticker of Adaptive Biotechnologies Corporation is 1HM.MU.
Which industry does the Adaptive Biotechnologies Corporation company belong to?
The Adaptive Biotechnologies Corporation industry is Biotechnology.
How many shares does Adaptive Biotechnologies Corporation have in circulation?
The max supply of Adaptive Biotechnologies Corporation shares is 163.84M.
What is Adaptive Biotechnologies Corporation Price to Earnings Ratio (PE Ratio)?
Adaptive Biotechnologies Corporation PE Ratio is now.
What was Adaptive Biotechnologies Corporation earnings per share over the trailing 12 months (TTM)?
Adaptive Biotechnologies Corporation EPS is -1.45 EUR over the trailing 12 months.
Which sector does the Adaptive Biotechnologies Corporation company belong to?
The Adaptive Biotechnologies Corporation sector is Healthcare.